Bristol Myers Squibb

News

KEYTRUDA is a prescription medicine used to treat a kind of skin cancer called melanoma

Keytruda 100mg/4mL Vial and Carton
2015

Merck & Co's Keytruda could catch BMS' rival with new lung c...

Merck & Co's Keytruda blockbuster immunotherapy could have yet another use, after it significantly boosted survival in patients with untreated squamous non-small cell lu

News

Known as Cabometyx in the US, the drug is licensed by Ipsen from Exelixis

EU approves Ipsen's Cabometyx in first line kidney cancer

Drug looks set to become core part of Ipsen's cancer offering

Views & Analysis

Digital health round-up: Nokia sells digital health unit bac...

Saga of Nokia's ill-fated digital health venture comes to a close

News

BMS strikes three-year cancer R&D deal with Flatiron

Bristol-Myers Squibb has struck a three-year with Flatiron Health that aims to make cancer R&D more efficient and patient-focused.

News

Ipsen takes on BMS as kidney cancer pill launches in EU

Cabometyx could take market share from Opdivo

News

Keytruda combo gets fast review in untreated lung cancer

Merck & Co's cancer drug Keytruda has been granted a priority review so that the immunotherapy medicine can be used in conjunction with chemotherapy to improve survival rates for untrea

Merck & Co's Keytruda could catch BMS' rival with new lung c...

EU approves Ipsen's Cabometyx in first line kidney cancer

Digital health round-up: Nokia sells digital health unit bac...

BMS strikes three-year cancer R&D deal with Flatiron

Ipsen takes on BMS as kidney cancer pill launches in EU

Keytruda combo gets fast review in untreated lung cancer

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Bristol Myers Squibb

Editor's Picks